National Institute on Aging; Notice of Closed Meeting, 2857-2858 [2014-00672]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 11 / Thursday, January 16, 2014 / Notices
Dated: January 10, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–00673 Filed 1–15–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
ehiers on DSK2VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Immunology
Integrated Review Group; Transplantation,
Tolerance, and Tumor Immunology Study
Section, Transplantation, Tolerance, and
Tumor Immunology.
Date: February 6, 2014.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin St. Francis, 335 Powell
Street, San Francisco, CA 94102.
Contact Person: Jin Huang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4199,
MSC 7812, Bethesda, MD 20892, 301–435–
1230, jh377p@nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Biobehavioral Regulation, Learning
and Ethology Study Section.
Date: February 10–11, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Dupont Hotel, 1500 New
Hampshire Avenue NW., Washington, DC
20036.
Contact Person: Mark D Lindner, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182,
MSC 7770, Bethesda, MD 20892, 301–435–
0913, lindnermd@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Neurological, Aging and Musculoskeletal
Epidemiology Study Section.
Date: February 13–14, 2014.
Time: 8:00 a.m. to 2:00 p.m.
VerDate Mar<15>2010
14:55 Jan 15, 2014
Jkt 232001
Agenda: To review and evaluate grant
applications.
Place: Dupont Circle Hotel, 1500 New
Hampshire Avenue NW., Washington, DC
20036.
Contact Person: Heidi B Friedman, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1012A,
MSC 7770, Bethesda, MD 20892, 301–435–
1721, hfriedman@csr.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Biomedical
Imaging Technology A Study Section.
Date: February 13–14, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bahia Resort Hotel, 998 West
Mission Bay Drive, San Diego, CA 92109.
Contact Person: Behrouz Shabestari, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5126,
MSC 7854, Bethesda, MD 20892, (301) 435–
2409, shabestb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 10–
234: Bioengineering Research Partnerships.
Date: February 13, 2014.
Time: 9:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Torrance South Bay, 3635
Fashion Way, Torrance, CA 90503.
Contact Person: Yvonne Bennett, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5199, MSC 7846, Bethesda, MD
20892, 301–379–3793, bennetty@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR13–282:
PET and SPECT Imaging Ligands as
Biomarkers for Drug Discovery.
Date: February 13, 2014.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Torrance South Bay, 3635
Fashion Way, Torrance, CA 90503.
Contact Person: Yvonne Bennett, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5199, MSC 7846, Bethesda, MD
20892, 301–379–3793, bennetty@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR13–137:
Bioengineering Research Grants.
Date: February 13, 2014.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Torrance South Bay, 3635
Fashion Way, Torrance, CA 90503.
Contact Person: Yvonne Bennett, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5199, MSC 7846, Bethesda, MD
20892, 301–379–3793, bennetty@csr.nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Electrical Signaling, Ion Transport,
and Arrhythmias Study Section.
Date: February 14, 2014.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
2857
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin St. Francis, 335 Powell
Street, San Francisco, CA 94102.
Contact Person: Yuanna Cheng, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4138,
MSC 7814, Bethesda, MD 20892, (301) 435–
1195, Chengy5@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
Dated: January 10, 2014.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–00675 Filed 1–15–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Clinical Trial
of a Multifactorial Fall Injury Prevention
Strategy in Older Persons.
Date: February 6, 2014.
Time: 11:15 a.m. to 2:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2c212, 7201
Wisconsin Avenue, Bethesda, Md 20892,
(Telephone Conference Call).
Contact Person: Ramesh Vemuri, Ph.D.,
Chief, Scientific Review Branch, National
Institute on Aging, National Institutes of
Health, 7201 Wisconsin Avenue, Suite 2C–
212, Bethesda, MD 20892, 301–402–7700,
rv23r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS).
E:\FR\FM\16JAN1.SGM
16JAN1
2858
Federal Register / Vol. 79, No. 11 / Thursday, January 16, 2014 / Notices
Dated: January 10, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–00672 Filed 1–15–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Patent License Agreement:
Treatment of Inflammatory Bowel
Disease (IBD), Including Ulcerative
Colitis and Crohn’s Disease
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
Start-Up Exclusive Patent License
Agreement to Paris Therapeutics, a
company having a place of business in
Santee, CA, to practice the inventions
embodied in the following patent
applications:
ehiers on DSK2VPTVN1PROD with NOTICES
SUMMARY:
1. U.S. Provisional Patent Application. No.
61/488,671, filed 20 May 2011 HHS Ref.
No.: E–073–2011/0–US–01 Titled:
Blockade of TL1A–DR3 Interactions to
Ameliorate T Cell Mediated Disease
Pathology and Antibodies Thereof
Inventors: Richard Siegel (NIAMS),
Francoise Meylan (NIAMS), and YunJeong Song (NIAMS)
2. PCT Application No. PCT/US2012/028926,
filed 13 March 2012 HHS Ref. No.: E–
073–2011/1–PCT–02 Titled: Blockade of
TL1A–DR3 Interactions to Ameliorate T
Cell Mediated Disease Pathology and
Antibodies Thereof Inventors: Richard
Siegel (NIAMS), Francoise Meylan
(NIAMS), and Yun-Jeong Song (NIAMS)
3. U.S. Patent Application No. 13/419,203,
filed 13 March 2012 HHS Ref. No.: E–
073–2011/1–US–01 Titled: Blockade of
TL1A–DR3 Interactions to Ameliorate T
Cell Mediated Disease Pathology and
Antibodies Thereof Inventors: Richard
Siegel (NIAMS), Francoise Meylan
(NIAMS), and Yun-Jeong Song (NIAMS)
4. Australian Patent Application claiming
priority to PCT/US2012/028926,
application number not available at this
time, filed 26 November 2013 HHS Ref.
No.: E–073–2011/1–AU–03 Titled:
Blockade of TL1A–DR3 Interactions to
Ameliorate T Cell Mediated Disease
Pathology and Antibodies Thereof
Inventors: Richard Siegel (NIAMS),
Francoise Meylan (NIAMS), and YunJeong Song (NIAMS)
5. Canadian Patent Application claiming
priority to PCT/US2012/028926,
application number not available at this
VerDate Mar<15>2010
14:55 Jan 15, 2014
Jkt 232001
time, filed 19 November 2013 HHS Ref.
No.: E–073–2011/1–CA–04 Titled:
Blockade of TL1A–DR3 Interactions to
Ameliorate T Cell Mediated Disease
Pathology and Antibodies Thereof
Inventors: Richard Siegel (NIAMS),
Francoise Meylan (NIAMS), and YunJeong Song (NIAMS)
6. European Patent Application No.
12790157.7, filed 14 November 2013
HHS Ref. No.: E–073–2011/1–EP–05
Titled: Blockade of TL1A–DR3
Interactions to Ameliorate T Cell
Mediated Disease Pathology and
Antibodies Thereof Inventors: Richard
Siegel (NIAMS), Francoise Meylan
(NIAMS), and Yun-Jeong Song (NIAMS)
7. Japanese Patent Application claiming
priority to PCT/US2012/028926,
application number not available at this
time, filed 20 November 2013 HHS Ref.
No.: E–073–2011/1–JP–06 Titled:
Blockade of TL1A–DR3 Interactions to
Ameliorate T Cell Mediated Disease
Pathology and Antibodies Thereof
Inventors: Richard Siegel (NIAMS),
Francoise Meylan (NIAMS), and YunJeong Song (NIAMS)
8. Korean Patent Application claiming
priority to PCT/US2012/028926,
application number not available at this
time, filed 18 December 2013 HHS Ref.
No.: E–073–2011/1–KR–07 Titled:
Blockade of TL1A–DR3 Interactions to
Ameliorate T Cell Mediated Disease
Pathology and Antibodies Thereof
Inventors: Richard Siegel (NIAMS),
Francoise Meylan (NIAMS), and YunJeong Song (NIAMS)
9. Mexican Patent Application No. MX/a/
2013/ 013329, filed 14 November 2013
HHS Ref. No.: E–073–2011/1–MX–08
Titled: Blockade of TL1A–DR3
Interactions to Ameliorate T Cell
Mediated Disease Pathology and
Antibodies Thereof Inventors: Richard
Siegel (NIAMS), Francoise Meylan
(NIAMS), and Yun-Jeong Song (NIAMS)
10. U.S. Provisional Patent Application No.
60/879,668, filed 10 January 2007, now
expired, HHS Ref. No.: E–011–2007/0–
US–01 Titled: Blockade of TL1A–DR3
Interactions to Ameliorate T Cell
Mediated Disease Pathology Inventors:
Richard Siegel (NIAMS) and Francoise
Meylan (NIAMS)
11. U.S. Patent Application No. 11/972,395,
filed 10 January 2008, now abandoned,
HHS Ref. No.: E–011–2007/0–US–02
Titled: Blockade of TL1A–DR3
Interactions to Ameliorate T Cell
Mediated Disease Pathology Inventors:
Richard Siegel (NIAMS) and Francoise
Meylan (NIAMS)
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
territory of the prospective Start-Up
Exclusive Patent License Agreement
may be worldwide, and the field of use
may be limited to ‘‘Antibodies against
TL1A for the Treatment of Inflammatory
Bowel Disease (IBD), including
Ulcerative Colitis and Crohn’s Disease.’’
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
January 31, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Patent License Agreement should be
directed to: Jaime M. Greene, M.S.,
Licensing and Patenting Manager, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5559; Facsimile: (301) 402–0220; Email:
greenejaime@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: This
technology concerns anti-mouse TNF
family ligand Tumor Necrosis Factor
(ligand) Superfamily, Member 15
(TL1A) and anti-human TL1A
monoclonal antibodies and the
hybridoma cell lines generating these
antibodies, as well as methods of
treating autoimmune inflammatory
diseases by blocking the interaction
between TL1A and Tumor Necrosis
Factor Receptor superfamily, Member
25 (DR3). This technology may be useful
for the development of diagnostics and
therapeutics for autoimmune
inflammatory disease.
The prospective Start-Up Exclusive
Patent License Agreement is being
considered under the small business
initiative launched on October 1, 2011
and will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR
part 404. The prospective Start-Up
Exclusive Patent License Agreement
may be granted unless the NIH receives
written evidence and argument, within
fifteen (15) days from the date of this
published notice, that establishes that
the grant of the contemplated Start-Up
Exclusive Patent License Agreement
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive Patent
License Agreement. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
DATES:
E:\FR\FM\16JAN1.SGM
16JAN1
]]>Agencies
[Federal Register Volume 79, Number 11 (Thursday, January 16, 2014)]
[Notices]
[Pages 2857-2858]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00672]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Clinical Trial of a Multifactorial Fall Injury Prevention
Strategy in Older Persons.
Date: February 6, 2014.
Time: 11:15 a.m. to 2:15 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, Suite
2c212, 7201 Wisconsin Avenue, Bethesda, Md 20892, (Telephone
Conference Call).
Contact Person: Ramesh Vemuri, Ph.D., Chief, Scientific Review
Branch, National Institute on Aging, National Institutes of Health,
7201 Wisconsin Avenue, Suite 2C-212, Bethesda, MD 20892, 301-402-
7700, rv23r@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS).
[[Page 2858]]
Dated: January 10, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-00672 Filed 1-15-14; 8:45 am]
BILLING CODE 4140-01-P
